EISAI INC. for EISAI INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. Treat and Reduce Obesity Act of 2017 (Bills not introduced 1Q17) Revisions to Medicare reimbursement programs
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
Defense DEF
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2018 (Bills not formally introduced as of filing)
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate tax reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
Health Issues HCR
Regulatory and legislative health care issues impacting pricing and access H.R. 1628 - American Health Care Act (AHCA) - To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. S. 204/H.R. 878 - Trickett Wendler Right To Try Act of 2017 S. 456/H.R. - Research to Accelerate Cures and Equity (RACE) for Children Act Senate Chronic Disease Initiative Regulatory and legislative health care issues, including the 340B program
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
Budget/Appropriations BUD
Legislation to amend the Affordable Care Act - Addressing pricing and access issues, prescription drug importation, potential reimbursement changes H.R. 1628 - American Health Care Act (AHCA) - To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. S. Con. Res. 3/H.Res. 48 - To establish the FY2017 congressional budget resolution, which provides a framework for congressional consideration of revenue, spending, and other budget-related legislation. S. Amdt. 178 - To amend S. Con. Res 3 to establish a deficit-neutral reserve fund relating to lower prescription drug prices for Americans by importing drugs from Canada
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.